BioNTech

BioNTech

Develops personalized immunotherapies with a focus on cancer medicine. Learn more

Launch date
Employees
Market cap
€26.7b
Enterprise valuation
€9.6b (Public information from Sep 2024)
Company register number HRB 48720 (Mainz)
Mainz Rhineland-Palatinate (HQ)

Financials

Estimates*

Edit
Revenues, earnings & profits over time
EUR2020202120222023202420252026
Revenues482m19.0b17.3b3.8b2.7b2.7b2.8b
% growth344 %3834 %(9 %)(78 %)(28 %)(1 %)2 %
EBITDA(42.1m)15.0b13.1b1.2b(949m)(1.0b)(1.0b)
% EBITDA margin(9 %)79 %76 %30 %(35 %)(38 %)(37 %)
Profit15.2m10.3b9.4b930m(523m)(636m)(681m)
% profit margin3 %54 %55 %24 %(19 %)(23 %)(25 %)
EV / revenue31.0x2.8x1.2x3.0x2.4x2.6x2.9x
EV / EBITDA-354.8x3.6x1.6x9.7x-6.8x-7.0x-7.7x
R&D budget645m<1m<1m1.8b---
R&D % of revenue134 %--47 %---

Source: Dealroom estimates

  • Edit
DateInvestorsAmountRound
-

N/A

-
N/A

N/A

Seed

N/A

Spinout
*

€225m

Series A
*

€80.0m

Valuation: €2.5b

18.3x EV/LTM Revenues

-97.2x EV/LTM EBITDA

Growth Equity VC
*

$325m

Valuation: $2.5b

16.6x EV/LTM Revenues

-88.4x EV/LTM EBITDA

Series B

$55.0m

Grant
N/A

$150m

Valuation: $3.4b

22.6x EV/LTM Revenues

-120.2x EV/LTM EBITDA

IPO

$55.8m

Debt

$250m

Private Placement VC

€100m

Debt

€375m

Grant
*
N/A

$150m

Post IPO Equity
*

$145m

Grant
Total Funding€1.4b

Recent News about BioNTech

Edit
More about BioNTechinfo icon
Edit

BioNTech is a biotechnology company focused on developing and commercializing innovative immunotherapies for the treatment of cancer and infectious diseases. Founded by scientists and physicians, BioNTech operates in the biopharmaceutical market, serving patients worldwide. The company leverages its expertise in mRNA technology to create personalized vaccines and therapies that stimulate the immune system to fight diseases. BioNTech collaborates with global partners to advance its diversified clinical pipeline, which includes treatments for various cancers and infectious diseases with high unmet medical needs. The company generates revenue through the development and commercialization of its therapies, as well as through partnerships and potential royalty payments from its lead cell therapy candidates. BioNTech is committed to equitable access to its innovative medicines, aiming to address pressing global health challenges.

Keywords: mRNA technology, immunotherapies, cancer treatment, infectious diseases, personalized vaccines, biopharmaceutical, clinical pipeline, global partnerships, innovative medicines, equitable access.

Tech stack

Group
Tech stackLearn more about the technologies and tools that this company uses.

Investments by BioNTech

Edit
Neon Therapeutics
ACQUISITION by BioNTech Jan 2020
MediGene
exited
InstaDeep
ACQUISITION by BioNTech Jan 2023
PhagoMed Biopharma
ACQUISITION by BioNTech Nov 2021
AexeRNA Therapeutics
ACQUISITION by BioNTech Nov 2023